



Docket No.: 19036/37157  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nobutaka Wakamiya

Application No.: 09/763,712

Filed: May 4, 2001 (§371)  
Aug. 24, 1999 (PCT)

For: Polynucleotides Encoding Human  
Collectin and Polypeptides Encoded  
Thereby

Confirmation No.: 9190

Group Art Unit: 1636

Examiner: Daniel Sullivan

**CERTIFICATE OF MAILING**

I hereby certify that this paper is being  
deposited with the U.S. Postal Service as First  
Class Mail in an envelope, postage prepaid,  
addressed to MS Amendment Commissioner  
for Patents, P.O. Box 1450, Alexandria, VA  
22313-1450 on August 6, 2004.

Kurt T. Buechle

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 C.F.R. § 1.97(c)). A check including the fee under §1.17(p) is enclosed.

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 19036/37157. A duplicate copy of this paper is enclosed.


Dated: August 6, 2004

Respectfully submitted,

By 

Kurt T. Buechle

Registration No.: 54,011  
MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Attorney for Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/763,712-Conf. #9190
				Filing Date	May 4, 2001
				First Named Inventor	Nobutaka Wakamiya
				Art Unit	1636
				Examiner Name	Daniel Sullivan
Sheet	1	of	1	Attorney Docket Number	19036/37157

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)			
	B6	WO 99/37767	07-29-1999	Fuso Pharmaceutical Ind. Ltd.	
	B7	WO 00/11161	03-02-2000	Fuso Pharmaceutical Ind. Ltd.	
	B8	WO 00/68380	11-16-2000	Bandman et al.	
	B9	WO 01/59107 and English translation of application as filed in U.S. with Preliminary Amendment (U.S. Application 10/203,860)	08-16-2001	Fuso Pharmaceutical Ind. Ltd.	X
	B10	WO 01/81401	11-01-2001	Fuso Pharmaceutical Ind. Ltd.	
	B11	JP 10-237611 English Translation of Japanese Patent Application No. 10-237611 filed on August 24, 1998 which is the priority case in U.S. Patent Application No. 09/763,712	08-24-1998	Nobutaka Wakamiya	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C35	Database EMBL, Online!, Homo sapiens chromosome 18 clone RP11-324G2 map 18, November 22, 1999, XP002279619.	
	C36	Supplementary European Search Report for EP 01 90 2805 dated June 3, 2004.	
	C37	Matsumoto A., et al., "Human macrophage scavenger receptors: primary structure, expression, and localization in atherosclerotic lesions" <i>Proc. Natl. Acad. Scie. USA</i> , 87:9133-9137 (1990).	
	C38	Kodama T., et al., "Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils" <i>Nature</i> , 343:531-535 (1990).	
	C39	Krieger M., et al., "Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP)" <i>Annu. Rev. Biochem.</i> 63:601-637 (1994).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/92 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 09/763,712

Attorney Docket No.: 19036/37157

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on August 6, 2004  
Date

Signature

Kurt T. Buechle

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant  
Copies of IDS References B6-B11 and C35-C39